ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio director Wesley Clark received a new stock option grant. The award covers 65,600 shares of Common Stock at an exercise price of $7.25 per share and expires on June 9, 2036. All 65,600 options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, if he continues as a service provider.
ImmunityBio director Cheryl Cohen received a new stock option grant. She was awarded options to buy 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, expiring on June 9, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in full only if she continues as a service provider. All 65,600 shares underlying the award will vest on the earlier of June 9, 2027 or the date immediately before the next annual meeting of stockholders. Following this grant, she holds 65,600 stock options directly.
ImmunityBio, Inc. director Christobel Selecky received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
Subject to Selecky continuing as a “Service Provider” under the company’s 2025 Equity Incentive Plan, 100% of the options will vest on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Following this grant, Selecky holds 65,600 stock options directly.
ImmunityBio, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Of 1,047,345,861 common shares outstanding as of April 13, 2026, 885,167,059 shares were represented, about 85% of eligible shares, establishing a quorum.
Stockholders re-elected nine directors, including Patrick Soon-Shiong, M.D., Cheryl L. Cohen, and seven other nominees, each to a one-year term ending at the 2027 annual meeting. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 882,420,139 votes in favor.
ImmunityBio director Barry J. Simon reported an open-market sale of 23,033 shares of Common Stock at a weighted average price of $7.1769 per share. The sale was executed on June 4, 2026 under a pre-arranged Rule 10b5-1 trading plan. After the transaction, he directly holds 2,827,788 shares.
ImmunityBio, Inc. entered an exclusive development and supply agreement with Japan BCG Laboratory giving it sole rights to develop, import, sell, and distribute the Tokyo-172 strain of BCG for bladder cancer in the United States and its territories after potential FDA approval. JBL will manufacture and supply the product, while ImmunityBio leads all U.S. preclinical, clinical, regulatory, and commercialization activities, with no payments due before approval and a commitment to purchase at least two batches per year afterward. The Tokyo strain’s Phase III SWOG S1602 data showed non-inferiority to TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer, and this agreement complements ImmunityBio’s existing recombinant BCG partnership to help address chronic U.S. BCG shortages.
ImmunityBio, Inc. reported strong Q1 2026 growth driven by ANKTIVA, but a large accounting loss. Net product revenue reached about $44.2 million for the quarter, up ~168% versus Q1 2025 and 15% over Q4 2025, reflecting continued uptake of ANKTIVA.
GAAP net loss attributable to common stockholders widened to $632.8 million, largely from non-cash changes in the fair value of warrant and derivative liabilities and a related-party convertible note tied to a higher stock price, plus a write-off of a convertible note receivable and higher R&D and SG&A expenses. Adjusted net loss, which excludes these items, was $86.2 million.
Cash, cash equivalents and marketable securities increased to $380.9 million as of March 31, 2026, supported by $223.9 million of net cash provided by financing activities in the quarter. ANKTIVA is now approved or authorized across five regulatory jurisdictions covering about 34 countries, with expanding commercial availability, and a pivotal BCG-naïve NMIBC trial is fully enrolled with a supplemental BLA submission planned in 2026.
ImmunityBio, Inc. is asking stockholders to elect nine directors and ratify Deloitte & Touche LLP as auditor at its June 9, 2026 virtual annual meeting. The proxy also highlights ANKTIVA’s first full commercial year, with 2025 net product revenue of about $113 million, a 700% increase, and 750% unit sales growth. ANKTIVA has reimbursement coverage for more than 240 million lives and a permanent J-code. The company reports new approvals in the UK, EU and an SFDA accelerated approval in metastatic non-small cell lung cancer, plus progress in BCG-naïve bladder cancer, glioblastoma and Phase 3 NSCLC trials. Executives received modest base salary increases and equity-based incentives tied to performance.